Daiichi Sankyo Company, Limited
4568.TMEDIUMScore: 36.8ADC Drug Manufacturing — Integrated Pharma + CDMO · Weight: 20%· Data as of 2026-06-07
Investment Thesis
Daiichi Sankyo invented the most successful antibody-drug conjugate in history: Enhertu (DS-8201), which reached $3.75B in combined FY2024 global sales with AstraZeneca and is approved in breast cancer, lung cancer, and gastric cancer. Their DXd-linker-payload technology is licensed to multiple global pharma partners (AstraZeneca, Merck, others), creating a manufacturing fee stream from each approved drug. Japan's regulatory environment requires that ADC drugs manufactured by Daiichi Sankyo for Japan carry Japan GMP certification — an inherent domestic manufacturing moat. Revenue +13% YoY in FY2026 to ¥2.12T confirms the ADC portfolio is scaling. ROE 15.8% is strong for a Japanese pharma company. ⚠️ AP02 FLAG: ¥75.7B manufacturing write-off in FY2025 for ADC overcapacity — reflects that Daiichi Sankyo expanded capacity ahead of demand in 2023-2024. The worst appears to be past.
Risk
1) AP02 CAPACITY HANGOVER (CONFIRMED): Daiichi Sankyo took ¥75.7B hit for ADC manufacturing overcapacity and cancelled the Odawara site expansion in FY2025. While the write-off is complete, asset utilization will be depressed until pipeline drugs advance to commercial stage. 2) ENHERTU DEPENDENCY: ~40-50% of value depends on continued Enhertu sales growth. New competitive ADCs from competitors (Immunomedics/Gilead Trodelvy, AbbVie) could slow market share gains. 3) HIGH VALUATION ON FORWARD BASIS: PE 17x trailing looks reasonable, but forward PE estimates vary widely (17-44x) due to uncertainty in pipeline timing. 4) REGULATORY RISK: ADC toxicity management is complex; any serious adverse event in late-stage ADC trials could affect the entire program.
Monitoring Trigger
If ADC manufacturing utilization (reported quarterly) exceeds 80% at any facility for 2 consecutive quarters: UPGRADE to HIGH conviction and ADD to 30% (overcapacity absorbed). If a 3rd major ADC partnership is announced (beyond AZ + Merck): ADD 5%. If Enhertu sales growth decelerates below 15% for 2 consecutive quarters: TRIM to 10%. Watch: FY2026 Q2 results (Nov 2026) for manufacturing capacity utilization data.
Key Dates
Key Metrics
Business Segments
| Segment | Revenue | Share | Description |
|---|---|---|---|
| Oncology (Enhertu, Vanflyta, Dato-DXd pipeline) | |||
| Cardiovascular / Other Rx | |||
| Drug Manufacturing & CDMO-equivalent |
Supply Chain Evidence
| Evidence | Customer | Product | Detail |
|---|---|---|---|
| confirmed | AstraZeneca (global commercialization partner) | Enhertu (trastuzumab deruxtecan, DS-8201) drug substance manufacturing and supply | Daiichi Sankyo and AstraZeneca have a $6.9B co-development collaboration for 3 ADC programs. Daiichi Sankyo is the primary manufacturer of the drug substance for Enhertu. Combined FY2024 sales reached $3.75 billion. This is a confirmed CDMO-equivalent relationship where Daiichi Sankyo manufactures for AstraZeneca's global distribution. |
| confirmed | Merck & Co. (MSD) | ADC manufacturing capacity for co-development programs (Merck signed $4B+ deal for DXd ADC) | Daiichi Sankyo entered a $4B+ collaboration with Merck in 2023 covering three DXd ADC programs. Merck explicitly confirmed a supply plan update in 2025. This creates a second major pharma manufacturing customer beyond AstraZeneca, diversifying Daiichi Sankyo's manufacturing revenue base. |
| confirmed | Japan hospital/oncology market (domestic manufacturing lock-in) | GMP oncology drug products manufactured in Japan (Enhertu, Vanflyta) under Japan GMP certification | All drugs approved in Japan require Japan-GMP manufacturing certification. Daiichi Sankyo's Japanese manufacturing facilities hold these certifications, creating a regulatory moat for Japan-marketed drugs. The ¥43T defense/healthcare budget supports domestic manufacturing of critical healthcare products. |